Search

Keiko Iwai,1 Emi Ushigome,1 Isao Yokota,2 Saori Majima,1 Naoko Nakanishi,1 Yoshitaka Hashimoto,1 Hiroshi Okada,3 Takafumi Senmaru,1 Masahide Hamaguchi,1 Mai Asano,1 Masahiro Yamazaki,1 Michiaki Fukui1 1Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602-8566, Japan; 2Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido 060-0808, Japan; 3Department of Endocrinology and Diabetology, Matsushita Memorial Hospital, Moriguchi, Osaka, 570-8540, JapanCorrespondence: Emi UshigomeDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii Cho, Kamigyo-ku, Kyoto-city, Kyoto 621-8585, JapanTel +81-75-251-5505Fax +81-75-252-3721Email emis@koto.kpu-m.ac.jpBackground: The coexistence of hypertension and diabetes mellitus significantly increases the risk of macrovascular complications in patients with diabetes. Home blood pressure is important because it is more strongly associated with target organ damage and total mortality than clinic blood pressure measurements. Regular moderate aerobic exercise has antihypertensive effects. This study aims to examine the effect of aerobic exercise therapy on blood pressure at home in patients with diabetes.Patients and Methods: In this crossover randomized controlled trial, 110 patients with type 2 diabetes will be randomly assigned to two groups: an exercise preceding group and an exercise lagging group. During the exercise period, patients will be instructed to walk either 30 minutes twice each day or 60 minutes once each day for at least 3 days per week. During the non-exercise period, patients will be permitted to perform physical activity associated with activities of daily life. Patients will be followed up for 56 days. The primary outcome will be the mean nocturnal blood pressure from day 24 to 28 during the exercise period compared to that during the non-exercise period. The secondary outcome will include variation in nocturnal blood pressure, mean blood pressure values and variation of morning and evening blood pressure from day 24 to 28 in the exercise period compared to the non-exercise period, body weight, body mass index and bioelectrical impedance analysis. Biochemical tests such as hemoglobin A1c level, blood glucose level, serum lipid profile, renal function, uric acid levels and liver function tests will also be measured.Discussion: This randomized controlled trial will provide critical information regarding the effectiveness of moderate exercise on nocturnal blood pressure reduction. If successful, the results of this randomized controlled trial may increase exercise motivation in people with diabetes and may lead to improvement or prevention of target organ damage and overall mortality.Trial Registration: Trial registration: University Hospital Medical Information Network, UMIN 000035973. Protocol version number: R000040969. Registration date: February 22, 2019. Recruitment began: June 19, 2019. The date of completion of recruitment: July 3, 2020. URL: http://www.umin.ac.jp.Keywords: nocturnal blood pressure, type 2 diabetes, aerobic exercise, randomized controlled trial

Iwai K, Ushigome E, Yokota I, et al. Diabetes Metab Syndr Obes. 2020;13:4747–4753. The authors have advised there was an error in the Institutional Review Board’s protocol version number. The correct protocol version number should read from R000040969 to ERB-C-1463-2. On page 4747, Abstract, Trial Registration section, the text “Protocol version number: R000040969. Registration date: February 22, 2019. Recruitment began: June 19, 2019” should read “Protocol version number: ERB-C-1463-2. Registration date: February 22, 2019. Recruitment began: June 19, 2019”. On page 4751, Ethics Approval and Informed Consent section, third sentence, the text “Protocol modifications will be approved by the medical research ethics committee of the Hospital of the Kyoto Prefectural University of Medicine (protocol reference number: R000040969)” should read “Protocol modifications will be approved by the medical research ethics committee of the Hospital of the Kyoto Prefectural University of Medicine (protocol reference number: ERB-C-1463-2)”. The authors wish to apologize for the error. Read the original article

Michiyo Asano,1 Junko H Ohyashiki,2 Chiaki Kobayashi-Kawana,1 Tomohiro Umezu,1,3 Satoshi Imanishi,3 Kenko Azuma,3 Daigo Akahane,1 Hiroaki Fujimoto,1 Yoshikazu Ito,1 Kazuma Ohyashiki11Department of Hematology, Tokyo Medical University, Tokyo, Japan; 2Department of Advanced Cellular Therapy, Tokyo Medical University, Tokyo, Japan; 3Department of Molecular Oncology, Institute of Medical Science, Tokyo Medical University, Tokyo, JapanPurpose: Monitoring response and resistance to 5-azacitidine (AZA) is essential when treating patients with myelodysplastic syndrome (MDS). To quantify methylated DNA not only in the promoter region but also in the gene body, we established a single-molecule methylation assay (SMMA).Patients and methods: We first investigated the methylation extent (expressed as methylation index [MI]) by SMMA among 28 MDS and 6 post-MDS acute myeloid leukemia patients. We then analyzed the MI in 13 AZA-treated patients.Results: Whole-blood DNA from all 34 patients had low MI values compared with healthy volunteers (P

Abstract: As a first step to study the relationship between fat accumulation and reproductive success in Japanese black bears (Ursus thibetanus japonicus Schlegel, 1857) with the focus on leptin, we [...]